Scottsdale 6/27/2013 3:00:00 AM
News / Financial Services

Anthera Pharmaceuticals (ANTH) Initiates BRIGHT-SC Phase 2 Clinical Study of Blisibimod for Treating IgA Nephropathy

QualityStocks would like to highlight Anthera Pharmaceuticals (NASDAQ: ANTH), focused on clinical development of novel medicines to treat serious human illnesses. The company is a biopharmaceutical company that develops and commercializes products to treat serious diseases associated with inflammation and autoimmune diseases.

In the company’s news,

Anthera Pharmaceuticals has announced the initiation of the BRIGHT-SC Phase 2 study of blisibimod, which is a novel inhibitor of B-cell activating factor (BAFF) for treating IgA nephropathy. A chronic autoimmune renal disease, IgA nephropathy is characterized by proteinuria and progression to end-stage renal disease.

A multicenter, placebo-controlled, double-blind Phase 2 clinical study, the BRIGHT-SC trial is anticipated to enroll a minimum of 48 patients from Asia Pacific geographies, who will then be randomized into one active treatment arm or one placebo arm. The study’s primary endpoint will be a reduction in proteinuria at 32 weeks. After the patients have completed eight weeks of therapy, Anthera intends to conduct an interim analysis of proteinuria. The study’s secondary endpoints will include the effects of blisibimod on estimated glomerular filtration rate (eGFR), plasma B cells and other kidney disease biomarkers.

Anthera met with the United States Food and Drug Administration (FDA) in May of this year to discuss the future of the IgA nephropathy development plan. The company has been encouraged by the outcome of its pre-Investigational New Drug meeting with the FDA, and the agency’s reception was positive regarding the use of proteinuria as a primary endpoint in studies of IgA nephropathy. The data from the BRIGHT-SC study design will aid Anthera in its efforts to obtain an accelerated approval for blisibimod in this potential orphan indication.

Anthera will meet with the Japanese Pharmaceutical Medical Devices Agency in the coming weeks to explore development strategies in Japan.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit  

To connect with QualityStocks via Facebook, please visit

To connect with QualityStocks via Twitter, please visit

Please read FULL disclaimer on the QualityStocks website:   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.